US5586226A
(en)
*
|
1990-05-16 |
1996-12-17 |
Canon Kabushiki Kaisha |
Control method and device for a unicolor printer
|
US5912410A
(en)
*
|
1990-06-15 |
1999-06-15 |
Scios Inc. |
Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
|
JP3510244B2
(ja)
*
|
1991-01-21 |
2004-03-22 |
エラン ファーマシューティカルス,インコーポレイテッド |
アルツハイマー病に関するテストおよびモデル
|
ATE243746T1
(de)
*
|
1992-01-07 |
2003-07-15 |
Elan Pharm Inc |
Transgene tiermodelle fur alzheimer-krankheit
|
US6610493B1
(en)
|
1993-06-17 |
2003-08-26 |
Brigham And Women's Hospital |
Screening compounds for the ability to alter the production of amyloid-β peptide
|
US6264915B1
(en)
|
1992-09-13 |
2001-07-24 |
The President And Fellows Of Harvard College |
Process for detecting potential carcinogens
|
US5436153A
(en)
*
|
1992-12-02 |
1995-07-25 |
Sprecher; Cindy A. |
Human amyloid protein precursor homolog and Kunitz-type inhibitor
|
EP0740702A1
(de)
*
|
1992-12-02 |
1996-11-06 |
Zymogenetics, Inc. |
Neuer menschlicher Amyloid - Protein - Vorläufer und Kunitztyp - Inhibitor
|
PT730643E
(pt)
|
1993-10-27 |
2001-06-29 |
Lilly Co Eli |
Animais transgenicos portadores do alelo de app com mutacao sueca
|
JPH07132033A
(ja)
*
|
1993-11-12 |
1995-05-23 |
Hoechst Japan Ltd |
アルツハイマー病モデルトランスジェニック動物
|
US5877399A
(en)
*
|
1994-01-27 |
1999-03-02 |
Johns Hopkins University |
Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
|
JPH09511388A
(ja)
|
1994-01-27 |
1997-11-18 |
リージェンツ オブ ザ ユニバーシティー オブ ミネソタ |
進行性神経疾患を持つヒト以外のトランスジェニック哺乳類
|
FR2716460B1
(fr)
*
|
1994-02-21 |
2002-08-09 |
Rhone Poulenc Rorer Sa |
Modèle animal de la maladie d'Alzheimer, préparation et utilisations.
|
US6025183A
(en)
*
|
1994-02-28 |
2000-02-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Transgenic animal assay system for anti-cholinesterase substances
|
WO1995034640A1
(en)
*
|
1994-06-13 |
1995-12-21 |
Henry Ford Health System |
A novel neuronal-neonatal gene: neuronatin
|
US6211428B1
(en)
*
|
1994-09-01 |
2001-04-03 |
Merck & Co., Inc. |
Transgenic mouse expressing a familial form of human amyloid precursor protein
|
US6114133A
(en)
*
|
1994-11-14 |
2000-09-05 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
|
US7427392B1
(en)
|
1994-11-14 |
2008-09-23 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
|
JP2000504202A
(ja)
*
|
1994-12-05 |
2000-04-11 |
メルク エンド カンパニー インコーポレーテッド |
本来のアミロイド前駆体タンパク質欠失トランスジェニック動物
|
US6187992B1
(en)
|
1994-12-05 |
2001-02-13 |
Merck & Co., Inc. |
Transgenic mouse having a disrupted amyloid precursor protein gene
|
US5777194A
(en)
*
|
1995-04-26 |
1998-07-07 |
Cephalon, Inc. |
Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
|
US5777093A
(en)
*
|
1995-05-16 |
1998-07-07 |
Ramot-University Authority For Applied Research & Industrial Development Ltd. |
cDNAs associated with ataxia-telangiectasia
|
US5728807A
(en)
*
|
1995-05-16 |
1998-03-17 |
Ramot-University Authority For Applied Research And Industrial Development, Ltd. |
Mutated proteins associated with ataxia-telangiectasia
|
US5858661A
(en)
*
|
1995-05-16 |
1999-01-12 |
Ramot-University Authority For Applied Research And Industrial Development |
Ataxia-telangiectasia gene and its genomic organization
|
US6187991B1
(en)
|
1995-05-23 |
2001-02-13 |
Pfizer Inc |
Transgenic animal models for type II diabetes mellitus
|
EP0832205A1
(de)
*
|
1995-06-07 |
1998-04-01 |
Athena Neurosciences, Inc. |
Methode zur identifizierung von arzneimitteln gegen der alzheimer krankheit mittels transgener tiermodelle
|
US6717031B2
(en)
*
|
1995-06-07 |
2004-04-06 |
Kate Dora Games |
Method for selecting a transgenic mouse model of alzheimer's disease
|
JPH11507821A
(ja)
*
|
1995-06-07 |
1999-07-13 |
アセナ ニューロサイエンシーズ,インコーポレイテッド |
トランスジェニック動物モデルを用いてアルツハイマー病治療薬を同定する方法
|
US5894078A
(en)
*
|
1996-02-26 |
1999-04-13 |
Advanced Bioconcept, Inc. |
Transgenic mouse expressing C-100 app
|
US6140309A
(en)
*
|
1996-03-12 |
2000-10-31 |
University Of South Florida |
Vasoactive effects and free radical generation by β-amyloid peptides
|
WO1997046664A1
(en)
|
1996-06-06 |
1997-12-11 |
University Of Washington |
Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
|
WO1998000532A2
(en)
|
1996-07-01 |
1998-01-08 |
Wright Jim A |
Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
|
WO1998003644A1
(en)
*
|
1996-07-24 |
1998-01-29 |
Novartis Ag |
Transgenic animal model for alzheimer disease
|
US20010016951A1
(en)
|
1996-07-24 |
2001-08-23 |
Bernd Sommer |
Transgenic animal model for alzheimer disease
|
WO1998003643A2
(en)
*
|
1996-07-22 |
1998-01-29 |
Smithkline Beecham Pharma Gmbh |
Transgenic animals with mutant human app or a4ct sequences
|
JP2000517185A
(ja)
|
1996-08-29 |
2000-12-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
新規なメタロプロテアーゼファミリーkuz
|
US6566089B1
(en)
*
|
1996-09-04 |
2003-05-20 |
Tularik Inc. |
Cell-based drug screens for regulators of gene expression
|
WO1998015172A2
(en)
*
|
1996-10-10 |
1998-04-16 |
Institut Pasteur |
Transgenic or mutated animal as model for a neuron deficit
|
US5898094A
(en)
*
|
1996-10-21 |
1999-04-27 |
University Of South Florida |
Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
|
US7973156B2
(en)
|
1997-08-21 |
2011-07-05 |
Quark Pharmaceuticals Inc. |
Hypoxia-regulated genes
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
ATE405661T1
(de)
|
1998-01-12 |
2008-09-15 |
Pedro Jose |
G protein-verwandte kinasemutanten in der essentiellen hypertonie
|
WO1999043697A1
(en)
*
|
1998-02-25 |
1999-09-02 |
The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno |
Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US6548261B1
(en)
|
1998-12-30 |
2003-04-15 |
Case Western Reserve University |
Alzheimer model for drug screening
|
EP1026251A3
(de)
*
|
1999-02-03 |
2000-09-06 |
Pfizer Products Inc. |
Transgene Tiere welche das menschliche p25 Gen exprimieren
|
WO2000059297A2
(en)
|
1999-04-06 |
2000-10-12 |
Harrington Arthritis Research Center |
Methods for tracking the progression of alzheimer's disease and identifying treatments using transgenic mice
|
US6670195B1
(en)
|
1999-05-26 |
2003-12-30 |
New York University |
Mutant genes in Familial British Dementia and Familial Danish Dementia
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
US6787318B1
(en)
|
1999-06-01 |
2004-09-07 |
Roskamp Research Institute, Llc |
Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US6541244B1
(en)
*
|
1999-06-07 |
2003-04-01 |
Cedars-Sinai Medical Center |
Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
|
AU5602100A
(en)
|
1999-06-09 |
2000-12-28 |
Arch Development Corporation |
Recombinant prion-like genes and proteins and materials and methods comprising same
|
US6875582B1
(en)
|
1999-08-19 |
2005-04-05 |
Omniscience Pharmaceuticals, Inc. |
Methods and targets of antibiotic resistance
|
US6864355B1
(en)
|
2000-05-02 |
2005-03-08 |
Yale University |
Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
|
CA2395416A1
(en)
|
1999-12-23 |
2001-06-28 |
Millennium Pharmaceuticals, Inc. |
P2y12 receptor
|
NZ520065A
(en)
|
2000-01-12 |
2006-02-24 |
Univ Yale |
Nogo receptor-mediated blockade of axonal growth
|
AU2001225441A1
(en)
|
2000-01-24 |
2001-07-31 |
Agricultural Research Organization The Volcani Center |
Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
|
US6982361B1
(en)
*
|
2000-02-25 |
2006-01-03 |
The Regents Of The University Of California |
Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal
|
ATE343562T1
(de)
*
|
2000-03-23 |
2006-11-15 |
Elan Pharm Inc |
Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
EP2267026A1
(de)
|
2000-04-12 |
2010-12-29 |
Human Genome Sciences, Inc. |
Albuminfusionsproteine
|
PE20020276A1
(es)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
|
EP1666452A2
(de)
|
2000-06-30 |
2006-06-07 |
Elan Pharmaceuticals, Inc. |
Verbindungen zur Behandlung der Alzheimerischen Krankheit
|
US6846813B2
(en)
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
DE60112942T2
(de)
*
|
2000-06-30 |
2006-06-22 |
Elan Pharmaceuticals, Inc., South San Francisco |
Verbindungen zur behandlung der alzheimerischen krankheit
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
HUP0300810A2
(hu)
|
2000-07-20 |
2003-08-28 |
M.G.V.S. Ltd. |
Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
US20030087286A1
(en)
*
|
2000-09-06 |
2003-05-08 |
Hodge Timothy A. |
Isolation of eukaryotic genomic DNA using magnetically responsive solid functionalized particles
|
US20050239125A1
(en)
*
|
2000-09-06 |
2005-10-27 |
Hodge Timothy A |
Methods for genotype screening
|
US20030082605A1
(en)
*
|
2000-09-06 |
2003-05-01 |
Hodge Timothy A. |
Genomic DNA detection method and system thereof
|
EP1978110B1
(de)
*
|
2000-09-06 |
2010-05-26 |
Transnetyx, Inc. |
Computer-basiertes Verfahren und System zum Screenen von genomischer DNS
|
US7494817B2
(en)
*
|
2000-09-06 |
2009-02-24 |
Transnet Yx, Inc. |
Methods for genotype screening using magnetic particles
|
US20050272085A1
(en)
*
|
2000-09-06 |
2005-12-08 |
Hodge Timothy A |
Methods for forensic and congenic screening
|
US20050266494A1
(en)
*
|
2000-09-06 |
2005-12-01 |
Hodge Timothy A |
System and method for computer network ordering of biological testing
|
US6900367B2
(en)
*
|
2000-09-29 |
2005-05-31 |
Novartis |
Transgenic Drosophila melanogaster expressing a β42 in the eye
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
US20020170078A1
(en)
*
|
2001-03-08 |
2002-11-14 |
Isabelle Mansuy |
Calcineurin-related transgenic mammals, compositions and methods
|
US7081561B2
(en)
|
2001-03-16 |
2006-07-25 |
The Regents Of The University Of California |
Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
|
ATE396174T1
(de)
*
|
2001-06-01 |
2008-06-15 |
Elan Pharm Inc |
Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
|
CA2450205A1
(en)
|
2001-06-13 |
2002-12-19 |
Elan Pharmaceuticals, Inc. |
Aminediols for the treatment of alzheimer's disease
|
MXPA04000140A
(es)
*
|
2001-06-27 |
2004-06-03 |
Elan Pharm Inc |
Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer.
|
US20070213407A1
(en)
*
|
2001-06-29 |
2007-09-13 |
Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc |
Compounds to treat Alzheimer's disease
|
EP1404664A1
(de)
*
|
2001-07-10 |
2004-04-07 |
Elan Pharmaceuticals, Inc. |
Aminodiole für die behandlung von alzheimer
|
CA2453444A1
(en)
*
|
2001-07-10 |
2003-01-23 |
Elan Pharmaceuticals, Inc. |
Diaminediols for the treatment of alzheimer's disease
|
US7297553B2
(en)
*
|
2002-05-28 |
2007-11-20 |
Nanosphere, Inc. |
Method for attachment of silylated molecules to glass surfaces
|
WO2003017994A1
(en)
*
|
2001-08-31 |
2003-03-06 |
Neurochem (International) Limited |
Amidine derivatives for treating amyloidosis
|
US20060014186A1
(en)
*
|
2001-09-04 |
2006-01-19 |
Hodge Timothy A |
Methods for genotype screening of a strain disposed on an adsorbent carrier
|
CA2462851A1
(en)
|
2001-10-04 |
2003-04-10 |
Elan Pharmaceuticals, Inc. |
Hydroxypropylamines
|
MXPA04004428A
(es)
*
|
2001-11-08 |
2004-09-10 |
Elan Pharm Inc |
Derivados de 2,3-diamino-2-hidroxipropano n,n`-sustituidos.
|
JP2005519874A
(ja)
*
|
2001-11-19 |
2005-07-07 |
ファルマシア アンド アップジョン |
アルツハイマー病の治療に有用なアミノジオール
|
US8178128B2
(en)
|
2001-12-05 |
2012-05-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Nanoparticles containing polymeric nucleic acid homologs
|
PT1463751E
(pt)
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Proteínas de fusão de albumina
|
US6992176B2
(en)
|
2002-02-13 |
2006-01-31 |
Technion Research & Development Foundation Ltd. |
Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
|
WO2003072041A2
(en)
*
|
2002-02-27 |
2003-09-04 |
Merck & Co., Inc. |
Assays to monitor amyloid precursor protein processing
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
AU2003303141A1
(en)
*
|
2002-04-30 |
2004-07-22 |
Elan Pharmaceuticals, Inc. |
Hydroxypropyl amides for the treatment of alzheimer's disease
|
UY27967A1
(es)
*
|
2002-09-10 |
2004-05-31 |
Pfizer |
Acetil 2-hindroxi-1,3-diaminoalcanos
|
EP1558737A4
(de)
|
2002-10-18 |
2008-06-11 |
Lg Life Sciences Ltd |
Mit krebserkrankungen assoziierte genfamilien
|
EP1565428A1
(de)
|
2002-11-27 |
2005-08-24 |
Elan Pharmaceuticals, Inc. |
Substituierte harnstoffe und carbamate
|
US7341847B2
(en)
*
|
2003-04-02 |
2008-03-11 |
Agency For Science, Technology And Research |
Promoter construct for gene expression in neuronal cells
|
AR044044A1
(es)
|
2003-04-21 |
2005-08-24 |
Elan Pharm Inc |
2-hidroxi-3-diaminoalcanos de benzamida
|
CL2004000848A1
(es)
*
|
2003-04-21 |
2005-01-28 |
Elan Pharmaceuticals Inc Pharm |
Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
|
IL155666A
(en)
*
|
2003-04-29 |
2013-12-31 |
Neurim Pharma 1991 |
Insomnia treatment
|
US7244739B2
(en)
*
|
2003-05-14 |
2007-07-17 |
Torreypines Therapeutics, Inc. |
Compounds and uses thereof in modulating amyloid beta
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
EP1633189B1
(de)
|
2003-05-19 |
2017-07-05 |
Prothena Biosciences Limited |
Verkürzte fragmente von alpha-synuklein bei lbd-krankheit
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
JP2007522129A
(ja)
*
|
2004-01-21 |
2007-08-09 |
エラン ファーマシューティカルズ,インコーポレイテッド |
アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法
|
US7262223B2
(en)
*
|
2004-01-23 |
2007-08-28 |
Neurochem (International) Limited |
Amidine derivatives for treating amyloidosis
|
CA2558034A1
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
US20050261273A1
(en)
*
|
2004-03-09 |
2005-11-24 |
Varghese John |
Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
|
CA2556826A1
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
|
US20050239790A1
(en)
*
|
2004-03-09 |
2005-10-27 |
Varghese John |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
SE0400707D0
(sv)
|
2004-03-22 |
2004-03-22 |
Bioarctic Neuroscience Ab |
Transgenic animal model
|
KR100574544B1
(ko)
*
|
2004-04-01 |
2006-04-27 |
주식회사 뉴로테크 |
돌연변이 βCTF99를 발현하는 알츠하이머병 유발형질전환 마우스
|
US7544855B2
(en)
*
|
2004-04-23 |
2009-06-09 |
Buck Institute |
Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
|
CA2567223A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Boehringer Ingelheim International Gmbh |
Treatment of diseases associated with altered level of amyloid beta peptides
|
JP4476050B2
(ja)
*
|
2004-06-30 |
2010-06-09 |
株式会社ニデック |
視野計
|
CA2573138A1
(en)
*
|
2004-07-09 |
2006-01-26 |
Elan Pharmaceuticals Inc. |
Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
|
WO2006010094A1
(en)
*
|
2004-07-09 |
2006-01-26 |
Elan Pharmaceuticals, Inc. |
Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
|
US8383637B2
(en)
*
|
2004-08-06 |
2013-02-26 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8436006B2
(en)
*
|
2004-08-06 |
2013-05-07 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8426429B2
(en)
*
|
2004-08-06 |
2013-04-23 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
GB0419124D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Proteome Sciences Plc |
Methods and compositions relating to Alzheimer's disease
|
JP2008511644A
(ja)
*
|
2004-08-27 |
2008-04-17 |
エラン ファーマシューティカルズ,インコーポレイテッド |
エタノール環式アミンアスパラギン酸プロテアーゼ阻害剤を用いて、アミロイドーシスを治療する方法
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
WO2006066089A1
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
EP2332408B1
(de)
|
2005-02-17 |
2013-11-13 |
Biogen Idec MA Inc. |
Behandlung neurologischer Störungen
|
EP1746092A1
(de)
|
2005-07-22 |
2007-01-24 |
Exonhit Therapeutics SA |
Verbindungen und Methoden zur Behandlung von Erkrankungen die in Verbindung mit beta-Amyloidpeptiden stehen
|
EP1913017A1
(de)
*
|
2005-08-03 |
2008-04-23 |
Boehringer Ingelheim International GmbH |
Substituierte ethan-1,2-diamine zur behandlung von alzheimer-krankheit ii
|
JP2009504611A
(ja)
*
|
2005-08-11 |
2009-02-05 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アルツハイマー病の治療用β−セクレターゼインヒビター
|
EP1915352A1
(de)
*
|
2005-08-11 |
2008-04-30 |
Boehringer Ingelheim International GmbH |
Verbindungen zur behandlung der alzheimer erkrankung
|
US20100168070A1
(en)
*
|
2005-08-11 |
2010-07-01 |
Niklas Heine |
Compounds for the treatment of alzheimer's disease
|
US20100144681A1
(en)
*
|
2005-08-11 |
2010-06-10 |
Klaus Fuchs |
Compounds for the treatment of alzheimer's disease
|
WO2007047305A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
|
JP2009511589A
(ja)
*
|
2005-10-12 |
2009-03-19 |
エラン ファーマシューティカルズ,インコーポレイテッド |
アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法
|
EP1984040A1
(de)
|
2006-01-31 |
2008-10-29 |
Multi Gene Vascular Systems, Inc. |
Arznei-eluierende intravaskuläre prothesen und verwendungsverfahren
|
US7932261B2
(en)
*
|
2006-02-06 |
2011-04-26 |
Janssen Pharmaceutica Nv |
Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
|
US7868022B2
(en)
*
|
2006-02-06 |
2011-01-11 |
Janssen Pharmaceutica Nv |
2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
|
WO2007092846A2
(en)
*
|
2006-02-06 |
2007-08-16 |
Janssen Pharmaceutica N.V. |
2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
|
WO2009017467A1
(en)
|
2007-07-27 |
2009-02-05 |
Elan Pharma International Limited |
Treatment of amyloidogenic diseases
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
JP5256199B2
(ja)
*
|
2006-08-07 |
2013-08-07 |
テヴァ バイオファーマシューティカルズ ユーエスエー,インコーポレーティッド |
アルブミン−インスリン融合タンパク質
|
CN102886052B
(zh)
|
2006-09-14 |
2014-07-30 |
迈德詹尼克斯医疗以色列有限公司 |
长效药物制剂
|
US8454948B2
(en)
|
2006-09-14 |
2013-06-04 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
FI3851447T3
(fi)
|
2006-10-12 |
2023-11-15 |
Bellus Health Inc |
Menetelmiä, yhdisteitä, koostumuksia ja vehikkeleitä 3-amino-1-propaanisulfonihapon vapauttamiseksi
|
PL381605A1
(pl)
|
2007-01-25 |
2008-08-04 |
Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akadmii Nauk |
Transgeniczne zwierzę i sposób jego otrzymywania
|
WO2008112898A2
(en)
|
2007-03-13 |
2008-09-18 |
The Children's Hospital Of Philadelphia |
Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
|
US7943590B2
(en)
|
2007-03-16 |
2011-05-17 |
Multi-Gene Vascular Systems Ltd. |
Compositions and methods for treating ophthalmic disorders
|
WO2008120202A2
(en)
|
2007-03-29 |
2008-10-09 |
Technion Research & Development Foundation Ltd. |
Antibodies, methods and kits for diagnosing and treating melanoma
|
HUE030719T2
(en)
|
2007-04-09 |
2017-05-29 |
Univ Florida |
RAAV vector formulations and methods comprising tyrosine-modified capsid proteins for their use
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
EP2164834A2
(de)
|
2007-07-06 |
2010-03-24 |
Boehringer Ingelheim International GmbH |
Substituierte aminochinazolinone, medikamente mit einer derartigen verbindung, ihre verwendung und herstellungsverfahren dafür
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
CA2713998A1
(en)
*
|
2008-01-28 |
2009-08-06 |
Janssen Pharmaceutica N.V. |
6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of.beta.-secretase (bace)
|
ES2397682T3
(es)
*
|
2008-01-29 |
2013-03-08 |
Janssen Pharmaceutica Nv |
Derivados de 2-amino-quinolina útiles como inhibidores de la beta-secretasa (BACE)
|
CA2714713C
(en)
|
2008-02-19 |
2018-02-27 |
The Children's Hospital Of Philadelphia |
Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
|
EP2116260A1
(de)
|
2008-04-16 |
2009-11-11 |
Freie Universität Berlin |
Screening-Verfahren von geeigneten Wirkstoffen zur Vorbeugung und Behandlung von Alzheimer (AD)
|
AU2009246134B2
(en)
|
2008-05-16 |
2016-03-03 |
The Children's Hospital Of Philadelphia |
Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US20110023152A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of cognition related genes in animals
|
US8871460B2
(en)
|
2009-11-09 |
2014-10-28 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
CN105821079B
(zh)
|
2010-04-23 |
2021-10-26 |
佛罗里达大学研究基金公司 |
用于治疗莱伯氏先天性黑蒙-1(lca1)的raav-鸟苷酸环化酶组合物及方法
|
AU2011268458B2
(en)
|
2010-06-15 |
2014-06-12 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
US10449177B2
(en)
|
2010-08-19 |
2019-10-22 |
Buck Institute For Research On Aging |
Methods of treating mild cognitive impairment (MCI) and related disorders
|
AU2013235422B2
(en)
|
2012-03-19 |
2016-12-15 |
Buck Institute For Research On Aging |
APP specific BACE inhibitors (ASBIs) and uses thereof
|
JP6471100B2
(ja)
|
2013-02-12 |
2019-02-13 |
バック・インスティテュート・フォー・リサーチ・オン・エイジング |
Bace仲介性appプロセシングを調節するヒダントイン
|
TW201522629A
(zh)
|
2013-10-24 |
2015-06-16 |
Medgenics Medical Israel Ltd |
提供治療多肽之持續遞送的微器官及其使用方法
|
US10704098B2
(en)
|
2014-10-29 |
2020-07-07 |
The Children's Hospital Of Philadelphia |
Diagnosis and treatment of genetic alterations associated with eosinophilic esophagitis
|
US10683552B2
(en)
|
2014-11-25 |
2020-06-16 |
Presidents And Fellows Of Harvard College |
Clonal haematopoiesis
|
US11168369B2
(en)
|
2014-11-25 |
2021-11-09 |
The Brigham And Women's Hospital, Inc. |
Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
|
WO2017035010A1
(en)
|
2015-08-21 |
2017-03-02 |
The Children's Hospital Of Philadelphia |
Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
|
CN108349905A
(zh)
|
2015-08-27 |
2018-07-31 |
南顿欧洲有限责任公司 |
用于app选择性bace抑制的组合物及其用途
|
EP3455223B1
(de)
|
2016-05-12 |
2023-11-08 |
Buck Institute for Research on Aging |
Verbindungen zur förderung der normalen verarbeitung von app
|
CN117043179A
(zh)
*
|
2021-01-28 |
2023-11-10 |
爱博瑞株式会社 |
用于治疗神经退行性疾病的基因治疗
|